Binding of the protein (green) to the surface of leukemia cells results in cell death via destruction of the cell's nucleus (dark red) into pieces. Credit: The Saban Research Institute of Children's Hospital Los Angeles
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells. It may also amplify the potency of standard treatment options such as chemotherapy and radiation therapy.
Their work, published online January 26 by the Journal of Clinical Investigation, demonstrated the efficacy and safety of the new fusion protein in mouse models of aggressive human leukemia using leukemia cells taken directly from patients with ALL.
Occurring at an annual rate of 35 to 40 cases per million people in the U.S., ALL represents approximately 25 percent of cancer diagnoses among children under the age of 15. Historically, ALL had a high mortality rate; nearly 80 percent of children who developed the disease did not survive long term. Today, those numbers have been reversed, with almost 80 percent of children affected by ALL achieving long- term survival.
"That's great news, unless your child is one of the 20 percent," said the study's principal investigator, Fatih M. Uckun, MD, PhD, of the Children's Center for Cancer and Blood Disease at CHLA and the Norris Comprehensive Cancer Center of the University of Southern California (USC). "Despite advances in available therapies, unmet and urgent needs remain in the fight against leukemia. We still have children with disease that our drugs can't help enough. And for patients who relapse, their chances of long-term survival are less than 20 percent. We've got to do better."
TNF-related apoptosis-inducing ligand (TRAIL) is a protein functioning as a ligand that induces apoptosis, or cell death. Produced by the immune system cells, it has the potential to cause apoptosis in tumor cells by binding to two so-called "death receptors", also known as TRAIL-receptor 1 and TRAIL-receptor 2.
"TRAIL is a naturally occurring part of the body's immune system that kills cancer cells without toxicity to normal cells. However, earlier clinical trials using TRAIL as a potential anti-cancer medicine candidate have not been successful, largely because of its propensity to bind, not only to cancer cells, but also to 'decoy' receptors," explained Uckun, who is also a professor of pediatrics at Keck School of Medicine of USC.
Uckun and collaborators discovered a previously unknown protein - CD19-Ligand - a natural ligand of human CD19, which is expressed by almost all ALL cells. They hypothesized that fusing it by genetic bioengineering to the portion of TRAIL (known as sTRAIL) that can kill cancer cells, would produce a powerful weapon against leukemia cells. Unlike chemotherapy drugs, this precision medicine candidate would seek out, bind and destroy only leukemia cells carrying CD19 as the target docking site.
They successfully accomplished this unique assembly of the two proteins in a single "fusion protein" and named this protein therapeutic candidate "CD19L-sTRAIL." In their study, Uckun and collaborators have demonstrated that their engineering converted sTRAIL into a much more potent "membrane-anchored" form that is capable of triggering apoptosis, even in the most aggressive and therapy-resistant form of human leukemia cells.
"Due to its ability to anchor to the surface of cancer cells via CD19, CD19L-sTRAIL was 100,000-fold more potent than sTRAIL, and consistently killed more than 99 percent of aggressive leukemia cells taken directly from children with ALL - not only in the test tube, but also in mice," said Uckun. Administering only two or three doses of CD19L-sTRAIL significantly improved the survival outcome of mice challenged with an otherwise invariably fatal dose of human leukemia cells, without side effects. Its therapeutic potency in mice was superior to that of standard chemotherapy combinations as well as radiation therapy.
"The biggest challenge is to cure patients who experience a recurrence of their cancer, despite intensive chemotherapy," Uckun concluded. "We are hopeful that the knowledge gained from this study will open a new range of effective treatment opportunities for children with recurrent leukemia."
Explore further: Researchers engineer a 'smart bomb' to attack childhood leukemia
Medical Xpress on facebook
Related Stories
Researchers engineer a 'smart bomb' to attack childhood leukemia
Nov 05, 2014
Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer—called B-lineage acute ...
Scientists bioengineer a protein to fight leukemia
Feb 18, 2011
Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body ...
Novel target found for chemotherapy-resistant leukemia cells
May 13, 2014
Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the ...
Researcher discovers way to overcome radiation resistance in leukemia
Sep 30, 2010
A team of researchers lead by Fatih M. Uckun, MD, PhD, of The Saban Research Institute of Childrens Hospital Los Angeles has determined that radiation resistance in leukemia can be overcome by selectively ...
Natural (born) killer cells battle pediatric leukemia
Aug 19, 2014
Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that ...
Recommended for you
New model better predicts breast cancer risk in African American women
56 minutes ago
Researchers from Boston University's Slone Epidemiology Center have developed a breast cancer risk prediction model for African- American women that found greater accuracy in predicting risk for the disease. The use of this ...
New breast cancer risk prediction model more accurate current model
59 minutes ago
A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer ...
Care eliminates racial disparity in colon cancer survival rates, study finds
59 minutes ago
For the past two decades, the National Cancer Institute has documented a persistent racial disparity in colon cancer survival rates in the United States.
Exercise regimen beneficial in head, neck CA radiation Tx
1 hour ago
(HealthDay)—For patients with head and neck cancers undergoing radiation therapy, an exercise regimen is better than a repetitive swallow regimen for swallowing function, according to a study published ...
Cooperation between cancer cells makes therapies ineffective, suggests new treatment
2 hours ago
Cooperation between cancer cells makes current therapies ineffective but also suggests new treatment
Phase 1 clinical trial of CUDC-101 'throws kitchen sink' at head and neck cancer
2 hours ago
Head and neck cancer is among the few solid tumors whose incidence is increasing in the U.S. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUCD-101 with radiation and chemotherapy were reported ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Binding of the protein (green) to the surface of leukemia cells results in cell death via destruction of the cell's nucleus (dark red) into pieces. Credit: The Saban Research Institute of Children's Hospital Los Angeles
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells. It may also amplify the potency of standard treatment options such as chemotherapy and radiation therapy.
Their work, published online January 26 by the Journal of Clinical Investigation, demonstrated the efficacy and safety of the new fusion protein in mouse models of aggressive human leukemia using leukemia cells taken directly from patients with ALL.
Occurring at an annual rate of 35 to 40 cases per million people in the U.S., ALL represents approximately 25 percent of cancer diagnoses among children under the age of 15. Historically, ALL had a high mortality rate; nearly 80 percent of children who developed the disease did not survive long term. Today, those numbers have been reversed, with almost 80 percent of children affected by ALL achieving long- term survival.
"That's great news, unless your child is one of the 20 percent," said the study's principal investigator, Fatih M. Uckun, MD, PhD, of the Children's Center for Cancer and Blood Disease at CHLA and the Norris Comprehensive Cancer Center of the University of Southern California (USC). "Despite advances in available therapies, unmet and urgent needs remain in the fight against leukemia. We still have children with disease that our drugs can't help enough. And for patients who relapse, their chances of long-term survival are less than 20 percent. We've got to do better."
TNF-related apoptosis-inducing ligand (TRAIL) is a protein functioning as a ligand that induces apoptosis, or cell death. Produced by the immune system cells, it has the potential to cause apoptosis in tumor cells by binding to two so-called "death receptors", also known as TRAIL-receptor 1 and TRAIL-receptor 2.
"TRAIL is a naturally occurring part of the body's immune system that kills cancer cells without toxicity to normal cells. However, earlier clinical trials using TRAIL as a potential anti-cancer medicine candidate have not been successful, largely because of its propensity to bind, not only to cancer cells, but also to 'decoy' receptors," explained Uckun, who is also a professor of pediatrics at Keck School of Medicine of USC.
Uckun and collaborators discovered a previously unknown protein - CD19-Ligand - a natural ligand of human CD19, which is expressed by almost all ALL cells. They hypothesized that fusing it by genetic bioengineering to the portion of TRAIL (known as sTRAIL) that can kill cancer cells, would produce a powerful weapon against leukemia cells. Unlike chemotherapy drugs, this precision medicine candidate would seek out, bind and destroy only leukemia cells carrying CD19 as the target docking site.
They successfully accomplished this unique assembly of the two proteins in a single "fusion protein" and named this protein therapeutic candidate "CD19L-sTRAIL." In their study, Uckun and collaborators have demonstrated that their engineering converted sTRAIL into a much more potent "membrane-anchored" form that is capable of triggering apoptosis, even in the most aggressive and therapy-resistant form of human leukemia cells.
"Due to its ability to anchor to the surface of cancer cells via CD19, CD19L-sTRAIL was 100,000-fold more potent than sTRAIL, and consistently killed more than 99 percent of aggressive leukemia cells taken directly from children with ALL - not only in the test tube, but also in mice," said Uckun. Administering only two or three doses of CD19L-sTRAIL significantly improved the survival outcome of mice challenged with an otherwise invariably fatal dose of human leukemia cells, without side effects. Its therapeutic potency in mice was superior to that of standard chemotherapy combinations as well as radiation therapy.
"The biggest challenge is to cure patients who experience a recurrence of their cancer, despite intensive chemotherapy," Uckun concluded. "We are hopeful that the knowledge gained from this study will open a new range of effective treatment opportunities for children with recurrent leukemia."
Explore further: Researchers engineer a 'smart bomb' to attack childhood leukemia
Medical Xpress on facebook
Related Stories
Researchers engineer a 'smart bomb' to attack childhood leukemia
Nov 05, 2014
Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer—called B-lineage acute ...
Scientists bioengineer a protein to fight leukemia
Feb 18, 2011
Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body ...
Novel target found for chemotherapy-resistant leukemia cells
May 13, 2014
Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the ...
Researcher discovers way to overcome radiation resistance in leukemia
Sep 30, 2010
A team of researchers lead by Fatih M. Uckun, MD, PhD, of The Saban Research Institute of Childrens Hospital Los Angeles has determined that radiation resistance in leukemia can be overcome by selectively ...
Natural (born) killer cells battle pediatric leukemia
Aug 19, 2014
Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that ...
Recommended for you
New model better predicts breast cancer risk in African American women
56 minutes ago
Researchers from Boston University's Slone Epidemiology Center have developed a breast cancer risk prediction model for African- American women that found greater accuracy in predicting risk for the disease. The use of this ...
New breast cancer risk prediction model more accurate current model
59 minutes ago
A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer ...
Care eliminates racial disparity in colon cancer survival rates, study finds
59 minutes ago
For the past two decades, the National Cancer Institute has documented a persistent racial disparity in colon cancer survival rates in the United States.
Exercise regimen beneficial in head, neck CA radiation Tx
1 hour ago
(HealthDay)—For patients with head and neck cancers undergoing radiation therapy, an exercise regimen is better than a repetitive swallow regimen for swallowing function, according to a study published ...
Cooperation between cancer cells makes therapies ineffective, suggests new treatment
2 hours ago
Cooperation between cancer cells makes current therapies ineffective but also suggests new treatment
Phase 1 clinical trial of CUDC-101 'throws kitchen sink' at head and neck cancer
2 hours ago
Head and neck cancer is among the few solid tumors whose incidence is increasing in the U.S. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUCD-101 with radiation and chemotherapy were reported ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment